v3.26.1
Collaborative, Licensing and Other Arrangements - Schedule of Funding Expenses (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Research and Development Arrangement, Contract to Perform for Others    
Research and development expense $ 541,224 $ 481,887
Amgen, Inc    
Research and Development Arrangement, Contract to Perform for Others    
BeOne’s portion of the development funding 58,048 40,519
Less: Amortization of research and development cost share liability 28,645 19,812
Research and development expense 29,403 $ 20,707
Remaining portion of development funding cap $ 72,346